DexCom, Inc., a leading developer of continuous glucose monitoring (CGM) systems, had plenty of wins to share with investors as it announced second-quarter results after the market closed on 28 July.
The San Diego, CA-based diabetes company reported second-quarter sales of $452m, well above the revenues of $416m predicted by a consensus among Wall Street analysts. Second-quarter revenues for 2020 marked a 34% increase year-over-year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?